Positron Emission Tomography (PET) Radiopharmaceuticals

The Department of the Army Medical Command's Madigan Army Medical Center is seeking sources capable of providing various radiopharmaceutical products for the Department of Radiology's Nuclear Medicine Service. These specialized medical products, including FDG, NaF, Calibration Source, Amyvid, Axumin, Cerianne, Tauvid, and Posluma (flotufolastat F 18 Injection), are critical for cancer diagnostic procedures that measure metabolic activity in body tissues. The radiopharmaceuticals are essential for providing cancer diagnostic services and patient care, requiring precise procurement due to their radioactive nature and extremely short expiration dates. Vendors must demonstrate capability to provide quick delivery services, as these products cannot be stocked and must be ordered on an as-needed basis per patient procedure. This pre-solicitation notice is posted on July 16, 2025, with responses due by July 22, 2025, providing potential contractors with six days to submit their capability statements.

This opportunity does not utilize any set-aside designation and is open to all qualified contractors under NAICS code 424210 for Drugs and Druggists' Sundries Merchant Wholesalers. The contract falls under PSC category 6505 for Drugs and Biologicals, reflecting the specialized pharmaceutical nature of the requirement. The specific quantities mentioned in the attached requirements include dosage ranges of 1-15mCi for FDG and NaF products, indicating the precise medical dosing requirements for these radiopharmaceuticals. No incumbent contractor information or budget ranges are disclosed in this sources sought notice. The time-sensitive nature of the procurement is emphasized throughout, with the critical requirement for rapid delivery capabilities being a key qualification criterion for potential vendors.